TScan Therapeutics to Participate in Upcoming Investor Conferences

$TCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $TCRX alert in real time by email

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference; the fireside chat will be held at the New York Marriott Marquis on Thursday, September 5, 2024 at 8:30 a.m. ET



  • H.C. Wainwright 26th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Tuesday, September 10, 2024 at 9:00 a.m. ET

Webcasts of the fireside chat and presentation will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcasts will be available on the Company's website for 90 days following the events.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.

Contacts

Heather Savelle

TScan Therapeutics, Inc.

VP, Investor Relations

857-399-9840

hsavelle@tscan.com

Maghan Meyers

Argot Partners

212-600-1902

TScan@argotpartners.com



Primary Logo

Get the next $TCRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCRX

DatePrice TargetRatingAnalyst
5/16/2024$12.00Buy
BTIG Research
5/13/2024$11.00Buy
Needham
6/22/2023$8.00Outperform
Wedbush
12/16/2021$21.00Buy
HC Wainwright & Co.
8/13/2021Outperform
Cowen & Co.
8/10/2021$22.00Overweight
Barclays
8/10/2021$22.00Overweight
Morgan Stanley
8/10/2021$21.00Buy
Jefferies
More analyst ratings

$TCRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

    WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event.

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

    WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

    WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank, for up to $52.5 million. The first tranche of $32.5 million, advanced at loan closing, will be used to retire the existing convertible debt with K2 Health Ventures and the remainder for general corporate purposes. TScan has the option through June 30, 2026, to draw the second $20.0 million tranche, subj

    $FCNCA
    $TCRX
    Major Banks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TCRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TCRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TCRX
SEC Filings

See more

$TCRX
Leadership Updates

Live Leadership Updates

See more
  • TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

    WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

    WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry. "We are pleased to welcome Dawn to TScan at such an exciting time in the Company's evolution," said Debora Barton, M.D., Chief Medical Officer. "Her expertise in cell and gene therapy clinical

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRX
Financials

Live finance-specific insights

See more
  • TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

    All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

    Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

    $AMGN
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

    Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i

    $AMGN
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TCRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more